Crossmark

HLA matching or CRISPR editing of HLA class I/II enables engraftment and effective function of allogeneic human regulatory T cell therapy in a humanized mouse transplantation model

Crossref DOI link: https://doi.org/10.1038/s41467-025-64945-3

Published Online: 2025-10-13

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

McCallion, Oliver https://orcid.org/0000-0002-5977-812X
Du, Weijie

Glaser, Viktor

Milward, Kate https://orcid.org/0000-0003-3019-4443
Short, Sarah https://orcid.org/0000-0002-7594-7915
Bilici, Merve

Cross, Amy

Stark, Helen https://orcid.org/0000-0002-9360-9864
Franke, Clemens https://orcid.org/0009-0009-0476-2807
Kath, Jonas https://orcid.org/0000-0001-7721-7978
Valkov, Mikhail

Yang, Mingxing

Amini, Leila https://orcid.org/0000-0003-4855-5905
Künkele, Annette https://orcid.org/0000-0002-8406-5412
Polansky, Julia K. https://orcid.org/0000-0003-4727-2540
Schmueck-Henneresse, Michael https://orcid.org/0000-0001-5964-9179
Volk, Hans-Dieter https://orcid.org/0000-0002-7743-6668
Reinke, Petra https://orcid.org/0000-0003-0771-4375
Wagner, Dimitrios L. https://orcid.org/0000-0002-2189-3579
Hester, Joanna https://orcid.org/0000-0002-7466-3849
Issa, Fadi https://orcid.org/0000-0002-8279-7732
License Information

Text and Data Mining valid from 2025-10-13

Version of Record valid from 2025-10-13
More Information

Article History

Received: 10 August 2023

Accepted: 1 October 2025

First Online: 13 October 2025

Competing interests

: HDV is the founder and C.S.O. of CheckImmune GmbH. H.D.V., P.R., and D.L.W. are co-founders of TCBalance Biopharmaceutical GmbH. All other authors declare that they have no other competing interests.

Document is current

Any future updates will be listed below